Citizens Financial Group Inc. RI Acquires New Stake in Insulet Corporation $PODD

Citizens Financial Group Inc. RI acquired a new stake in Insulet Corporation (NASDAQ:PODD) during the 2nd quarter, Holdings Channel reports. The institutional investor acquired 3,311 shares of the medical instruments supplier’s stock, valued at approximately $504,000.

A number of other large investors also recently bought and sold shares of PODD. BlackRock Inc. acquired a new stake in shares of Insulet in the 2nd quarter worth $1,018,582,000. Norges Bank purchased a new stake in shares of Insulet in the fourth quarter valued at about $300,794,000. Arrowstreet Capital Limited Partnership increased its stake in shares of Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after acquiring an additional 1,011,369 shares during the period. Bank of New York Mellon Corp purchased a new position in Insulet during the second quarter worth about $60,615,000. Finally, Deutsche Bank AG purchased a new position in Insulet during the second quarter worth about $51,153,000.

Insider Activity

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of Insulet stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the transaction, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on PODD shares. Evercore set a $180.00 price objective on Insulet in a report on Monday, July 6th. Oppenheimer downgraded Insulet from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Barclays reduced their price target on Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a report on Thursday, May 7th. Citigroup lifted their price target on Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Finally, Wells Fargo & Company downgraded Insulet from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $255.00 to $144.00 in a research note on Wednesday, August 5th. Fourteen equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $195.40.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s recent operating performance provides a counterpoint to the legal concerns: the company’s latest reported quarter exceeded analyst expectations for both earnings and revenue, with revenue up 23.5% year over year. This may be supporting investor confidence.
• Neutral Sentiment: Multiple firms, including Glancy Prongay Wolke & Rotter, Robbins LLP, Rosen Law Firm, Portnoy Law Firm, and others, are soliciting investors who purchased Insulet securities between February 21, 2025, and May 26, 2026. The firms cite a federal securities class action and an August 31, 2026 deadline for investors to seek appointment as lead plaintiff. Deadline Alert: Insulet Corporation Shareholders
• Negative Sentiment: The complaints allege that Insulet made materially false or misleading statements about manufacturing controls and the safety and reliability of its Omnipod insulin-delivery products. The allegations reportedly center on two voluntary medical-device corrections and claims that broader manufacturing defects were not adequately disclosed. The allegations have not been proven in court. Insulet Corporation Stockholders Class Action
• Negative Sentiment: One law-firm notice says investor confidence deteriorated after the Omnipod corrections and attributes an approximately $90-per-share decline to the alleged disclosures. If the litigation produces further recalls, regulatory action, settlements, or evidence of persistent quality problems, Insulet could face higher costs and slower growth. PODD Deadline Alert from Levi & Korsinsky

Insulet Stock Performance

Shares of PODD opened at $151.51 on Thursday. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. Insulet Corporation has a 52-week low of $126.40 and a 52-week high of $354.88. The company has a 50-day simple moving average of $154.75 and a 200-day simple moving average of $185.83. The company has a market capitalization of $10.51 billion, a PE ratio of 28.32, a P/E/G ratio of 1.17 and a beta of 1.10.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. During the same quarter in the previous year, the firm earned $1.17 earnings per share. The firm’s revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities research analysts predict that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.